Press release
Investigation announced for Long-Term Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
An investigation on behalf of current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares.
Investors who are current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: KPTI stocks follows a lawsuit filed against Karyopharm Therapeutics Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: KPTI stocks, concerns whether certain Karyopharm Therapeutics Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that the defendants violated Federal Securities Laws. The plaintiff claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock during the time period of March 2, 2017 and February 22, 2019, and violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm Therapeutics Inc. (NASDAQ: KPTI common stock in or traceable to the Company's public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018.
More specifically, the plaintiff alleges that the Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer, that the, Defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor", and that the Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile”, while in reality, selinexor was unsafe with limited efficacy.
Those who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) here
News-ID: 1865920 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Karyopharm
Veterinary Oncology Market Exclusive Report with Detailed Study Analysis | Morph …
The latest Veterinary Oncology Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future.…
Endometrial Cancer Market: Trends in Diagnosis, Treatment Innovations, and Risin …
A new report published by CoherentMI, titled "Endometrial Cancer Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Endometrial Cancer market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The endometrial cancer market is estimated to be valued at USD 26.53 Bn in 2024 and is expected to reach USD 39.10…
Hematological Cancers Market Global Industry Trend Analysis and Forecast 2023 - …
"Worldwide Market Reports Offering with upto 70% Discount on Premium Hematological Cancers Market Report On Purchases With Single User Access and Unlimited User Access"
The Hematological Cancers Market 2023 research report Provides analyses of the market's size, share, growth, trends, cost structure, and statistically significant information for the global market. The study presents an accurate representation of the market's current situation. It includes unique and innovative coming detailed financial and…
Hematological Cancers Market With in-detailed Competitor Analysis, Forecast to 2 …
Global Hematological Cancers Market Overview:-
Stratagem Market Insights has evaluated the global Hematological Cancers market in its latest research report. The research report, titled Global Hematological Cancers Market 2022 by Manufacturers, Regions, Type, and Application, Forecast to 2028, presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of…
Global Pet Cancer Therapeutics Market Size, Trends and Forecast 2027 By | Karyop …
The Pet Cancer Therapeutics Market study provides a thorough but completes analysis of the worldwide Pet Cancer Therapeutics market, including all of the major company profiles that have an impact on the market's growth and breadth. The study is written in accordance with data that could be critical to the market's progress. The study gives the customer a clear picture of the current market's obstacles and issues, and it helps…
DiGeorge Syndrome Drug Market Worth Observing Growth : CELLECTAR BIOSCIENCES, IN …
The DiGeorge Syndrome Drug Market analysis report brings into focus studies about market definition, market segmentation, and competitive analysis in the market. The precise and state-of-the-art information provided via this report helps businesses get aware about the types of consumers, consumer's demands and preferences, their point of view about the product, their buying intentions, their response to particular product, and their varying tastes about the specific product already existing in…
